Laia Montoliu-Gaya

Apr 27, 2023 | nature.com | Laia Montoliu-Gaya |Cecile Tissot |Agathe Vrillon |Wagner S. Brum |Juan Lantero-Rodriguez |Johanna Nilsson | +5 more

AbstractBlood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease identification across the AD continuum and the link to pathology is limited. This is partly due to heterogeneity in analytical methods.

Mar 29, 2023 | thelancet.com | Laia Montoliu-Gaya |Daniel Alcolea |Nicholas Ashton

SummaryBackgroundThe diagnosis of symptomatic Alzheimer's disease is a clinical challenge in adults with Down syndrome. Blood biomarkers would be of particular clinical importance in this population. The astrocytic Glial Fibrillary Acidic Protein (GFAP) is a marker of astrogliosis associated with amyloid pathology, but its longitudinal changes, association with other biomarkers and cognitive performance have not been studied in individuals with Down syndrome.